T-cell lymphomas(TCL)are a heterogeneous group of aggressive non-Hodgkin lymphomas consisting of over 23 subtypes such as Natural Killer/T-Cell lymphoma(NKTL).Despite its high prevalence in Asian countries,TCL remains...
T-cell lymphomas(TCL)are a heterogeneous group of aggressive non-Hodgkin lymphomas consisting of over 23 subtypes such as Natural Killer/T-Cell lymphoma(NKTL).Despite its high prevalence in Asian countries,TCL remains under-investigated with significant gaps impeding its precise in histological diagnosis,molecular subtyping and targeted *** remains the backbone of treatment for TCL,with very limited targeted therapeutic *** previous works focus on the genomic profiling of TCL using high-throughput technologies and the data is correlated with clinic-pathological *** aims are to 1)identify potential therapeutic targets and develop new therapeutics for these TCLs;and 2)uncover novel predictive biomarkers related to the clinical response to *** this talk,I will first present our recent studies in translating lymphoma genomics to new therapeutics in ***,I will describe our unpublished data in deciphering resistant mechanisms to targeted-HDAC therapy in NKTL.
暂无评论